J&J Tries Transitioning To Health Care Solutions Firm Through JHI Subsidiary
This article was originally published in The Pink Sheet Daily
Executive Summary
The healthcare conglomerate has been testing out-of-the-box ways to address current key challenges for its stakeholders, namely improving the patient experience, reducing the cost-burden to the health care system, and ultimately enhancing the marketplace in which it sells its products.
You may also be interested in...
J&J’s New Innovation Centers Test Immersion Theory Of Access
Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?
Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.